On September 15, 2023, NeuroBo Pharmaceuticals achieved a significant milestone by administering the initial dose of its experimental drug, DA-1241, to the first patient participating in a Phase 2a clinical trial. This trial aims to assess the drug’s potential in treating nonalcoholic steatohepatitis (NASH), a liver condition.
The trial has been meticulously designed as a 16-week endeavor, involving multiple medical centers. It will follow a randomized, double-blind, placebo-controlled, parallel-group structure, consisting of two distinct parts. NeuroBo’s Investigational New Drug (IND) application received clearance from the U.S. Food and Drug Administration (FDA), granting the company permission to commence the trial.
Approximately 200 patients, all diagnosed with biopsy-confirmed NASH, are anticipated to participate in the trial. The primary objective of this study is to evaluate the safety and tolerability of DA-1241. Additionally, the trial’s secondary objectives encompass assessing the drug’s efficacy in reducing liver fat content, improving liver enzymes, and analyzing other relevant biomarkers associated with NASH.
As of August 2023, NeuroBo boasted a healthy financial position, with cash and cash equivalents amounting to $28.7 million. With the first patient set to receive treatment in September 2023, the company is well-prepared to embark on this crucial clinical trial.
ATOS<br /> seems to be an invalid ticker
Please provide a valid Ticker
ATOS Stock Performance on September 15, 2023: Mixed Results and Decline in Earnings Growth
ATOS stock had a mixed performance on September 15, 2023. The stock opened at $0.83 and traded within a range of $0.78 to $0.83. The trading volume was 363,499 shares. The market capitalization of ATOS is $107.0M and it operates in the Health Technology sector under the Pharmaceuticals: Major industry. The company’s earnings growth in the past year was -20.83% and it experienced a further decline of -14.29% in earnings growth this year. The P/E ratio and Price/Sales ratio were not provided. The Price/Book ratio was 0.92. On September 15, 2023, ATOS had a slight decrease of -0.00, resulting in a percentage change of -0.99%. The next reporting date for ATOS is November 15, 2023, with an EPS forecast of -$0.07 for the current quarter. ATOS is headquartered in Seattle, Washington.
ATOS Stock Surges on Positive Analyst Forecasts, Offering Strong Growth Potential
On September 15, 2023, Atossa Therapeutics Inc (ATOS) experienced a significant surge in its stock performance, driven by positive analyst forecasts. According to data from CNN Money, the three analysts offering 12-month price forecasts for ATOS have a median target of $5.00, with a high estimate of $5.50 and a low estimate of $4.00. The consensus among the three polled investment analysts is to buy stock in Atossa Therapeutics Inc. The unanimous buy rating suggests that these analysts believe ATOS has strong growth potential and may outperform the market in the coming months. Investors are likely buoyed by the optimistic price targets set by these analysts. With a median target of $5.00, ATOS stock is expected to experience substantial appreciation. The high estimate of $5.50 further reinforces the positive sentiment surrounding the company’s future performance. These forecasts indicate that ATOS may be an attractive investment opportunity for those seeking significant returns.